Dr Grunwald Reveals Fascinating Insight into Rates of Disease Progression in Low-Risk Myelofibrosis

Dr Grunwald Reveals Fascinating Insight into Rates of Disease Progression in Low-Risk Myelofibrosis

Understanding Disease Progression in Low-Risk Myelofibrosis Patients


Myelofibrosis is a rare type of cancer of the bone marrow that causes abnormal scar tissue to form. This scarring can cause a number of unpleasant symptoms, such as fatigue, anemia, and abdominal discomfort. However, not all patients with myelofibrosis experience the same level of disease progression. In this article, we will explore the latest research on the disease progression rates in low-risk myelofibrosis patients enrolled in the MOST study.

What is Myelofibrosis?

Before we dive into the specifics of the MOST study, it’s important to understand what myelofibrosis is and how it progresses. Myelofibrosis is classified as a type of myeloproliferative neoplasm (MPN), which means that it involves the overproduction of certain types of blood cells. In myelofibrosis, the bone marrow produces too many blood cells called megakaryocytes, which are responsible for the formation of platelets. This excess production leads to the formation of scar tissue in the bone marrow, which can interfere with the body’s normal blood production process.

The MOST Study

The MOST study is a large, international study designed to better understand the natural history of myelofibrosis. The study involves patients with different risk levels of myelofibrosis, ranging from low-risk to high-risk. In this article, we will focus specifically on the results of the study in low-risk patients.

Study Design

The MOST study is a prospective study, which means that patients are followed over time to track changes in their condition. The low-risk patients in the study were monitored for up to 5 years. During this time, they underwent regular testing to track disease progression, including blood tests, bone marrow biopsies, and imaging tests.


The results of the MOST study confirmed that many patients with low-risk myelofibrosis have a relatively stable condition over time. Specifically, the study found that:

  • Only a small percentage of patients with low-risk myelofibrosis progressed to high-risk disease during the 5-year study period.
  • Most low-risk patients had slow or stable disease progression, with only minor changes in their blood counts and bone marrow results over time.
  • A small number of low-risk patients experienced disease regression, meaning that their disease improved over time.

Prognostic Factors

While the MOST study found that low-risk myelofibrosis patients often have stable disease over time, some patients may still be at higher risk for disease progression. There are several prognostic factors that can help predict a patient’s likelihood of experiencing disease progression. These factors include:

  • Age
  • Sex
  • Hemoglobin levels
  • Platelet count
  • Spleen size
  • Gene mutations

TP53 Mutations in CLL

In a separate study, Dr. Bertossi explored the prognostic role of TP53 mutations in chronic lymphocytic leukemia (CLL). CLL is another type of blood cancer that can progress slowly or quickly, depending on the patient’s individual risk factors. TP53 mutations are associated with a higher risk of disease progression and poorer outcomes in CLL patients. However, the role of TP53 mutations in myelofibrosis is still being studied.


The MOST study provides valuable information about the natural history of myelofibrosis, particularly in low-risk patients. While myelofibrosis is a serious condition, many patients with low-risk disease can expect to have slow or stable disease progression over time. Prognostic factors, such as gene mutations, can help identify patients who may be at higher risk of disease progression. With continued research and clinical trials, we will hopefully be able to improve outcomes for patients with this rare condition.

Originally Post From https://www.onclive.com/view/dr-grunwald-on-the-rates-of-disease-progression-in-low-risk-myelofibrosis

Read more about this topic at
Prefibrotic versus overtly fibrotic primary myelofibrosis
Prognostic relevance of serum LDH and BM reticulin …

Outpatient CART-cell Administration for Non-Hodgkin Lymphoma: Safety and Feasibility

Blincyto gets nod as consolidation for CD19-Positive Philadelphia Chromosome–Negative.